Кашель при новой коронавирусной инфекции (COVID-19): рациональные подходы к фармакотерапии [PDF]
, 2022 Cough is one of the most frequent symptoms of the new coronavirus infection (COVID-19). It reduces the quality of life and contributes to the development of life-threatening conditions.Aim.
A. А. Зайцев +5 more
core +1 more source
Tropical Food Spices: A Promising Panacea for the Novel Coronavirus Disease (COVID‐19)
eFood, Volume 1, Issue 5, Page 347-356, October 2020., 2020 GRAPHICAL ABSTRACT Coronavirus disease 2019 (COVID‐19) is an infectious fatal disease caused by the Severe Acute Respiratory Syndrome Coronavirus‐2 (SARS‐CoV‐2) with millions of individuals infected globally within few months of its outbreak. During infection, the SARS‐CoV‐2 main protease binds directly to Angiotensin‐converting Enzyme 2 (ACE2 ...
Adedayo O. Ademiluyi +2 more
wiley +1 more source
, 2023 BackgroundCurrently, there are no guidelines or consensus statements about the usage of inhaled mucoactive drugs in pediatric respiratory disease conditions from an Indian perspective.ObjectiveTo develop a practical consensus document to help ...
Rashmi R. Das (17544537) +9 more
core +1 more source
"The importance of mucoregulators in S.O.M."
, 1992 LAURIELLO, MARIA +2 more
openaire +2 more sources
Canadian Respiratory Journal, Volume 10, Issue A, Page 11A-33A, 2003., 2003 Chronic obstructive pulmonary disease (COPD) is a common cause of disability and death in Canada. Moreover, morbidity and mortality from COPD continue to rise and the economic burden is enormous. The main goal of the Canadian Thoracic Society (CTS) Evidence‐Based Guidelines is to optimize early diagnosis, prevention and management of COPD in Canada ...
Denis E O’donnell +11 more
wiley +1 more source
[Use of the mucoregulator ascoril for respiratory diseases].
Terapevticheskii arkhiv, 2012 The paper deals with the use of the combined mucoregulatory drug ascoril in pulmonological care. Due to its multicomponent composition, the drug has mucoregulatory properties that combine a bronchodilator effect and an ability to dilute sputum and to synthesize the surfactant.
openaire +3 more sources
Acebrophylline: an airway mucoregulator and anti-inflammatory agent
Monaldi Archives for Chest Disease, 2016 Acebrophylline is an airway mucus regulator with antiinflammatory action. The drug’s approach involves several points of attack in obstructive airway disease. The molecule contains ambroxol, which facilitates various steps in the biosynthesis of pulmonary surfactant, theophylline-7 acetic acid whose carrier function raises blood levels of ambroxol ...
openaire +5 more sources
Содержание и распределение гликопротеинов в эпителиоцитах бронхов при хроническом бронхите (Лектиногистохимическое исследование) [PDF]
, 1994 The luminescence examination of bronchial biopsy specimens taken from 52 patients with primary chronic bronchitis and 8 healthy volunteers (control group) was carried out using lectin sets marked with FITC having the various carbohydrate specificity ...
В. Л. Коваленко +3 more
core
Stepwise treatment in patients with isolated thermal inhalation injury
Терапевтический архив, 2013 AIM: To evaluate the efficiency of stepwise treatment in patients with isolated thermal inhalation injury (TIJ)/MATERIAL AND METHODS: The study enrolled 101 patients with isolated TIJ.
S A Degtiareva +3 more
doaj
L1077P CFTR pathogenic variant function rescue by Elexacaftor-Tezacaftor-Ivacaftor in cystic fibrosis patient-derived air-liquid interface (ALI) cultures and organoids: in vitro guided personalized therapy of non-F508del patients. [PDF]
Respir Res, 2023 Lo Cicero S +15 more
europepmc +1 more source